Study of Weight-Reducing Effect and Safety of Rimonabant In Obesity in ASIA (RIO-ASIA)
NCT00325546
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
643
Enrollment
INDUSTRY
Sponsor class
Conditions
Obesity
Interventions
DRUG:
Rimonabant (SR141716)
DRUG:
Placebo
Sponsor
Sanofi